Ejection fraction in heart failure revisited-where does the evidence start?

被引：21
作者：
Boehm, Michael [1 ]
Bewarder, Yvonne [1 ]
Kindermann, Ingrid [1 ]
机构：
[1] Saarland Univ, Univ Klinikum Saarlandes, Klin Innere Med 3, Homburg, Germany
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷 / 25期
关键词：
CONVERTING-ENZYME-INHIBITORS; VENTRICULAR SYSTOLIC FUNCTION; RANDOMIZED-TRIAL; CANDESARTAN; SPIRONOLACTONE; HYPERTENSION; ENALAPRIL; MORTALITY; BLOCKADE; OUTCOMES;
D O I：
10.1093/eurheartj/ehaa281
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2363 / 2365
页数：3
相关论文
共 50 条
[31]   New pharmacotherapy for heart failure with reduced ejection fraction [J].
Sotirakos, Sara ;
Wheen, Peter ;
Spiers, James ;
Armstrong, Richard .
EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2020, 18 (07) :405-414
[32]   Redefining heart failure phenotypes based on ejection fraction [J].
Campbell, Ross T. ;
Petrie, Mark C. ;
McMurray, John J. V. .
EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 (12) :1634-1635
[33]   Heart failure: What does ejection fraction have to do with it? [J].
Iwano, Hiroyuki ;
Little, William C. .
JOURNAL OF CARDIOLOGY, 2013, 62 (1-2) :1-3
[34]   Effect of heart failure pharmacotherapies in patients with heart failure with mildly reduced ejection fraction [J].
Schupp, Tobias ;
Bertsch, Thomas ;
Reinhardt, Marielen ;
Abel, Noah ;
Schmitt, Alexander ;
Lau, Felix ;
Abumayyaleh, Mohammad ;
Akin, Muharrem ;
Weiss, Christel ;
Weidner, Kathrin ;
Behnes, Michael ;
Akin, Ibrahim .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 31 (11) :1347-1360
[35]   Pharmacological treatment options for heart failure with reduced ejection fraction: A 2022 update [J].
Hellenkamp, Kristian ;
Nolte, Kathleen ;
von Haehling, Stephan .
EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (06) :673-680
[36]   The Role of Mineralocorticoid Receptor Antagonists in the Management of Heart Failure with Preserved Ejection Fraction [J].
Papagiannis, Achilleas ;
Alkagiet, Stelina ;
Tziomalos, Konstantinos .
CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (46) :5525-5527
[37]   Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF [J].
Butt, Jawad H. ;
Docherty, Kieran F. ;
Jhund, Pardeep S. ;
Boer, Rudolf A. ;
Bohm, Michael ;
Desai, Akshay S. ;
Howlett, Jonathan G. ;
Inzucchi, Silvio E. ;
Kosiborod, Mikhail N. ;
Martinez, Felipe A. ;
Nicolau, Jose C. ;
Petrie, Mark C. ;
Ponikowski, Piotr ;
Bengtsson, Olof ;
Langkilde, Anna Maria ;
Schou, Morten ;
Sjostrand, Mikaela ;
Solomon, Scott D. ;
Sabatine, Marc S. ;
McMurray, John J., V ;
Kober, Lars .
EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (03) :513-525
[38]   Treatment of Heart Failure with Mid-Range Ejection Fraction: What Is the Evidence [J].
Koufou, Eleni-Evangelia ;
Arfaras-Melainis, Angelos ;
Rawal, Sahil ;
Kalogeropoulos, Andreas P. .
JOURNAL OF CLINICAL MEDICINE, 2021, 10 (02) :1-13
[39]   Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction [J].
Abumayyaleh, Mohammad ;
El-Battrawy, Ibrahim ;
Behnes, Michael ;
Borggrefe, Martin ;
Akin, Ibrahim .
FUTURE CARDIOLOGY, 2020, 16 (04) :227-236
[40]   Diastolic heart failure. Heart failure with preserved ejection fraction [J].
Dovjak, P. .
ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2013, 46 (01) :71-81
12345